Regeneron Pharmaceuticals (REGN -0.4%) has exercised an option under its April 2016 agreement with Intellia Therapeutics (NTLA +0.8%) to reduce its share of global development costs and profits related to transthyretin amyloidosis (ATTR) to 25% from 50%.
Intellia will continue to lead development and commercialization of ATTR products while Regeneron maintains options to in-license exclusive rights to as many as 10 targets, including ATTR, as well as opt-in rights to co-develop and co-commercialize up to five liver targets selected by Intellia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.